{"id":434944,"date":"2021-02-12T07:08:29","date_gmt":"2021-02-12T12:08:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=434944"},"modified":"2021-02-12T07:08:29","modified_gmt":"2021-02-12T12:08:29","slug":"oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/","title":{"rendered":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., Feb.  12, 2021  (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%\">\u00a0<\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%\">\u00a0<\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%\">\n            <strong>Conference: <\/strong>LifeSci Partners Precision Oncology Day<br \/><strong>Date: <\/strong>February 17, 2021<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <strong>Conference: <\/strong>Cowen 41<sup>st<\/sup> Annual Health Care Conference<br \/><strong>Date: <\/strong>March 1, 2021<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <strong>Conference: <\/strong>Oppenheimer 31st Annual Healthcare Conference<br \/><strong>Date: <\/strong>March 17, 2021<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About OncXerna Therapeutics<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company\u2019s deep understanding of how to prospectively identify patients based on the dominant, RNA-based biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna\u2019s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. For more information on OncXerna, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tEAvLBVbjGX284KkqSwUZ4RhVRK_lKyrFWD0aryMh-vGuERVuWOJ07Zsr16HC4Zk1NtRubGuqILvodwBOxTRHg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">oncxerna.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>About OncXerna\u2019s RNA-based Biomarker Platform<\/strong>\n      <\/p>\n<p align=\"justify\">Existing precision medicines target only approximately 10% of cancers\u2014those with gene mutations or oncogenic drivers for a small number of genes. Using its proprietary biomarker platform, OncXerna is leveraging the company\u2019s deep understanding of tumor biology at the RNA level to identify the dominant biology underlying a patient\u2019s cancer. OncXerna\u2019s first biomarker panel is specific to the tumor microenvironment (TME Panel-1). Initial results from TME Panel-1 reveal 4 different dominant biologies, demonstrating the presence of specific patient subgroups and their predictive value in responding to treatment. OncXerna is further optimizing the biomarker platform\u2019s tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.<\/p>\n<p align=\"justify\">\n        <strong>About Navicixizumab<\/strong>\n      <\/p>\n<p align=\"justify\">Navicixizumab is an investigational anti-DLL4\/VEGF bispecific antibody that has demonstrated antitumor activity in patients who have progressed on Avastin\u00ae (bevacizumab) in a Phase 1a\/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal, or fallopian tube cancer in patients who have received at least three prior therapies and\/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.<\/p>\n<p align=\"justify\">\n        <strong>About Bavituximab<\/strong>\n      <\/p>\n<p align=\"justify\">Bavituximab is an investigational antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. OncXerna\u2019s clinical trials currently combine bavituximab with KEYTRUDA\u00ae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.<\/p>\n<p align=\"justify\">KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Ashley R. Robinson<br \/>LifeSci Partners, LLC<br \/>arr@lifesciadvisors.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7761eab3-c00f-421f-b70b-52003f899557\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences: \u00a0 \u00a0 \u00a0 Conference: LifeSci Partners Precision Oncology DayDate: February 17, 2021 \u00a0 \u00a0 \u00a0 Conference: Cowen 41st Annual Health Care ConferenceDate: March 1, 2021 \u00a0 \u00a0 \u00a0 Conference: Oppenheimer 31st Annual Healthcare ConferenceDate: March 17, 2021 \u00a0 \u00a0 About OncXerna Therapeutics OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company\u2019s deep understanding of how to prospectively identify patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OncXerna Therapeutics to Participate at the Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-434944","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences: \u00a0 \u00a0 \u00a0 Conference: LifeSci Partners Precision Oncology DayDate: February 17, 2021 \u00a0 \u00a0 \u00a0 Conference: Cowen 41st Annual Health Care ConferenceDate: March 1, 2021 \u00a0 \u00a0 \u00a0 Conference: Oppenheimer 31st Annual Healthcare ConferenceDate: March 17, 2021 \u00a0 \u00a0 About OncXerna Therapeutics OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company\u2019s deep understanding of how to prospectively identify patients &hellip; Continue reading &quot;OncXerna Therapeutics to Participate at the Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-12T12:08:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences\",\"datePublished\":\"2021-02-12T12:08:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/\"},\"wordCount\":594,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/\",\"name\":\"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\",\"datePublished\":\"2021-02-12T12:08:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk","og_description":"WALTHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences: \u00a0 \u00a0 \u00a0 Conference: LifeSci Partners Precision Oncology DayDate: February 17, 2021 \u00a0 \u00a0 \u00a0 Conference: Cowen 41st Annual Health Care ConferenceDate: March 1, 2021 \u00a0 \u00a0 \u00a0 Conference: Oppenheimer 31st Annual Healthcare ConferenceDate: March 17, 2021 \u00a0 \u00a0 About OncXerna Therapeutics OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company\u2019s deep understanding of how to prospectively identify patients &hellip; Continue reading \"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-12T12:08:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences","datePublished":"2021-02-12T12:08:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/"},"wordCount":594,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/","name":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==","datePublished":"2021-02-12T12:08:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MTgyNyMzOTczNDI4IzUwMDA3MjgxMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-to-participate-at-the-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OncXerna Therapeutics to Participate at the Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/434944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=434944"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/434944\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=434944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=434944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=434944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}